Patents by Inventor Peter Collin Gregory

Peter Collin Gregory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amylases for pharmaceutical use
    Patent number: 8017351
    Abstract: The pharmaceutical use of amylases related to Bacillus alpha-amylases of SEQ ID NOs: 1-3, optionally in combination with a lipase and/or a protease. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The amylases of SEQ ID NOs: 1-3 are variants of amylases from Bacillus stearothermophilus, Bacillus licheniformis and Bacillus sp. The amylases of the invention have an improved efficacy in vivo, an improved pH-profile, a high specific activity, and/or an improved starch degradation profile.
    Type: Grant
    Filed: June 16, 2006
    Date of Patent: September 13, 2011
    Assignees: Novozymes A/S, Solvay Pharmaceuticals GmbH
    Inventors: Allan Svendsen, Peter Collin Gregory
  • Amylases for Pharmaceutical Use
    Publication number: 20090035293
    Abstract: The pharmaceutical use of amylases related to Bacillus alpha-amylases of SEQ ID NOs: 1-3, optionally in combination with a lipase and/or a protease. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The amylases of SEQ ID NOs: 1-3 are variants of amylases from Bacillus stearothermophilus, Bacillus licheniformis and Bacillus sp. The amylases of the invention have an improved efficacy in vivo, an improved pH-profile, a high specific activity, and/or an improved starch degradation profile.
    Type: Application
    Filed: June 16, 2006
    Publication date: February 5, 2009
    Applicants: Novozymes A/S, Solvay Pharmaceuticals
    Inventors: Allan Svendsen, Peter Collin Gregory